JBIO
Jade Biosciences, Inc.
There isn't enough reported data to score JBIO yet.
JBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
JBIO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
JBIO PE Valuation
JBIO has no meaningful PE right now: it lost money over the past year.
JBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect JBIO's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
JBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$3.57 | +$26.69 |
| Q1 2026 | -$3.67 | +$55.83 |
| Q4 2025 | -$6.25 | +$79.15 |
| Q3 2025 | -$11.14 | +$93.16 |
| Q2 2025 | -$30.26 | +$79.29 |
| Q1 2025 | -$59.50 | +$46.55 |
| Q4 2024 | -$85.40 | +$15.05 |
| Q3 2024 | -$104.30 | -$8.40 |
JBIO is still losing money, but far less than before: $3.57 per share over the past year, against $109.55 at its worst in mid-2024.
JBIO Quarterly Revenue
JBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$24.1M | -$21.7M |
| Q4 2023 | -$14.9M | +$5K |
| Q3 2023 | -$15.6M | -$5.9M |
| Q2 2023 | -$15M | -$6M |
| Q1 2023 | -$11.4M | -$5.8M |
| Q4 2022 | -$14.9M | -$1.7M |
| Q3 2022 | -$9.8M | -$3.2M |
JBIO has burned cash in almost every quarter: −$82M over the past year, against −$57M the year before.
JBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.7% | +3.3M shares |
| 1 year | +7272% | +60.2M shares |
| 3 years | +8524% | +60.3M shares |
JBIO has 61M diluted shares, up 7272% from a year ago.
JBIO Net Leverage
JBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
JBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 17.7 | Oversold |
JBIO's weekly RSI is 45 (neutral) and its Stochastic is 18 (oversold).
JBIO PE vs Healthcare Sector
JBIO has no meaningful PE right now: it lost money over the past year.
JBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $14.5 | 9.4% above |
| 20 week MA | $18.1 | 13% below |
| 50 week MA | $17.7 | 10% below |
| 100 week MA | $28.6 | 44% below |
| 200 week MA | $271.1 | 94% below |
JBIO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 94% below its 200-week average.
JBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $697.9 | $363.3 | -48% |
| 2022 | $363.3 | $976.9 | +169% |
| 2023 | $976.9 | $792.1 | -19% |
| 2024 | $792.1 | $93.5 | -88% |
| 2025 | $93.5 | $16.5 | -82% |
| 2026 YTD | $16.5 | $15.9 | -3.5% |
JBIO has finished three years in a row lower, and it's down 3.5% so far in 2026.